Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 11 March 2022

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, was introduced to regulate the quality, safety, and efficacy of therapeutic goods, including medicines, medical devices, and blood products. It fills the legislative gap by establishing a framework for the approval, manufacturing, advertising, and monitoring of these goods. The Act aims to protect public health by ensuring that therapeutic goods available in Australia meet stringent standards. The Therapeutic Goods Administration, as the delegate of the Secretary of the Department of Health, enforces the provisions of the Act, which includes the authority to suspend manufacturing licenses to address non-compliance or other serious issues. This authority ensures the safety and integrity of the therapeutic goods market in Australia, aligning with the policy objective of safeguarding public health through rigorous regulatory oversight.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, ensuring that such products are of an acceptable standard for public use. The Act applies to entities and individuals involved in the manufacture, importation, supply, or advertisement of therapeutic goods, including medicines, medical devices, and blood products. Its jurisdictional reach is national, applying to all activities within the Commonwealth of Australia. The Act sets out the framework for the licensing of manufacturers, importers, and suppliers, and includes provisions for the suspension or cancellation of licences where necessary for public safety. This is evident in the recent notice issued by the Therapeutic Goods Administration, where the licence of Cyclopet Pty Ltd was suspended at the manufacturer’s request from 19 August 2021 to 19 August 2022. The Act also allows for the creation of subordinate instruments to extend or refine the application of its provisions, although this specific notice does not reference any such instruments. The Act does not provide specific exclusions or exemptions but rather establishes thresholds and criteria that entities must meet to maintain their licences.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") encompasses various provisions related to the regulation of therapeutic goods in Australia. Section 41(1)(d) (1) is particularly relevant here, as it empowers the Secretary to suspend a licence for the manufacture of therapeutic goods under specific circumstances. The Act requires that any such suspension must be communicated in writing (2). In this instance, Katherine Clark, the Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, has exercised this authority in relation to Cyclopet Pty Ltd. The licence in question, MI-2010-LI-03381-3, has been suspended at the request of the manufacturer, Cyclopet Pty Ltd (3). The obligations imposed by the Act on entities such as Cyclopet Pty Ltd include adherence to the manufacturing standards set forth by the Therapeutic Goods Administration (TGA) (4). This involves ensuring that all therapeutic goods produced meet the necessary safety, quality, and efficacy standards. The suspension of the licence indicates a significant concern regarding compliance with these standards, which could stem from issues such as non-compliance with manufacturing practices, quality control failures, or other regulatory breaches (5). The Act requires manufacturers to maintain detailed records and documentation to demonstrate compliance with these standards, and the suspension may be a result of deficiencies in these records or practices. In terms of the consequences of breaching the provisions of the Act, Section 41(1)(d) allows for the suspension of a licence as a means of enforcement (6). The suspension itself is a formal action that restricts the manufacturer's ability to produce therapeutic goods during the specified period, thereby limiting their ability to distribute or sell these goods within Australia. This action serves both as a punitive measure and a means of ensuring that the manufacturer takes corrective action to address the underlying issues before resuming operations (7). Failure to comply with the Act can lead to more severe penalties, including the revocation of the licence, which would permanently prohibit the manufacturer from producing therapeutic goods (8). Additionally, the manufacturer could face legal action, including fines or imprisonment, under other sections of the Act or related legislation.